Organoid-Guided drug trial offers hope for cystic fibrosis patients with rare mutations

NCT ID NCT06468527

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a triple-drug combination (dirocaftor/posenacaftor/nesolicaftor) in 41 adults with cystic fibrosis who have rare CFTR gene mutations not covered by existing treatments. Participants were chosen based on lab tests using their own intestinal organoids to predict who might benefit. The goal was to see if the drugs improve lung function and other measures like sweat chloride and weight.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Azienda Ospedaliera Universitaria Integrata

    Verona, Italy

  • CHU de Nice

    Nice, France

  • Charité Universitätsmedizin Berlin

    Berlin, Germany

  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

    Milan, Italy

  • Hospital Vall d'Hebron

    Barcelona, Spain

  • Hospital de Santa Maria

    Lisbon, Portugal

  • Hôpital Larrey CHU Toulouse

    Toulouse, France

  • Instituto Giannina Gaslini

    Genova, Italy

  • Medizinische Hochschule Hannover

    Hanover, Germany

  • Ospedale Pediatrico Bambino Gesù

    Rome, Italy

  • Royal Brompton Hospital

    London, United Kingdom

  • Sahlgrenska University Hospital, Gothenburg CF center

    Gothenburg, Sweden

  • UMC Utrecht

    Utrecht, Utrecht, 3584 CX, Netherlands

  • UZ Leuven

    Leuven, Vlaams-Brabant, Belgium

  • University Hospital Southampton

    Southampton, United Kingdom

  • University Hospitals Birmingham NHS Foundation Trust

    Birmingham, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.